Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iISLET
- Development stage
- Unknown
- Lead developer
- All Life Biotechnology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
01
Overview
iISLET is an induced pluripotent stem cell (iPSC)-derived islet cell therapy being developed by All Life Biotechnology for the treatment of Type 1 Diabetes and other conditions involving insulin deficiency or demyelination. The therapy involves the differentiation of iPSCs into functional, insulin-producing islet cells, which are then transplanted into the patient. The primary goal is to restore endogenous insulin production and achieve long-term glycemic control, potentially eliminating the need for external insulin injections. It is currently in early-phase clinical development, with trials exploring its efficacy in both diabetes and demyelinating diseases.
Beyond the preview
Go deeper on iISLET.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iISLET.